Aegera
-
Aegera Therapeutics Initiates Clinical Study in Hong Kong
Aegera Therapeutics has announced the successful completion of a dose-ranging Phase 1 study and the initiation of a randomized Phase 2 study of AEG35156. This is in combination with sorafenib for the treatment of patients with advanced hepatocellular…
Aegera | 11 February 2010
